About Us

Sprectroo is a subsidiary of Ailynix that has created a AI-Driven Drug Derivatization and Repurposing Platform that incorporates Deep Learning, Blockchain and Genomics.

Mission

Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition. It’s the vision of Sprectroo Founding Team to collaborate with international Pharma and Biotechnology companies identifying promising candidate drugs,

Definition

Drug Repurposing is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication.
Drug Derivatization is a technique used in chemistry which transforms a chemical compound into a product of similar chemical structure, called a derivative.

Drug repositioning for personalized medicine

Human diseases can be caused by complex mechanisms involving aberrations in numerous proteins and pathways. With recent advances in genomics, elucidating the molecular basis of disease on a personalized level has become an attainable goal. In many cases, relevant molecular targets will be identified for which approved drugs already exist, and the potential


Platform

AIDRRP is a Genomics Driven Drug Derivatization and Repositioning Platform that implements Deep Learning, (DL) with Blockchain and Genomics de novo design technology called "derivatization design and discovery" that applies artificial-intelligence-assisted forward in Silico synthesis for the generation of near neighbor lead analogues as well as scaffold variations.
The several attractive features of the methodology include synthetic feasibility, reagent availability and cost data associated with each new molecule; thus, detailed synthetic assessment is automatically generated during the design.

Core Technologies/Features

Integrated Platform, Innovative Solutions
Chemical derivatization for the analysis of drugs
Integrated theoretical & experimental data
Integrated Genomic data
Developing and evaluating primary and secondary screening tests
Generating series of small molecules targeting novel mechanisms of action
Modulating therapeutic targets to induce specific biological responses

OUR FOCUS


Collaborate with North American Pharma and Bio-Pharma companies through equity and/or cooperative Joint Venture partnerships focusing on drug derivatization and repurposing of approved and failed drugs.


Collaborate with Asia’s Pharma and Bio-Pharma companies through equity and/or cooperative Joint Venture partnerships focusing on drug derivatization of approved and failed drugs.


Collaborate with European and South African Pharma and Bio-Pharma companies through equity and/or cooperative Joint Venture partnerships focusing on drug derivatization and repurposing of approved and failed drugs.

PARTNERS


A global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

FOUNDING TEAM

Nabila Berrabia

Co-Founder, Chief Product Officer

Siham Lakrikh, PhD

Co-Founder, Chief Research Officer

Sajda Ashra, PhD

Co-Founder, Chief Scientific Officer

Daniel Kwong

Advisor - Business Operations

Henok G. Woldu, Ph.D

Advisor – Data Science

Rick Sayegh, MD, MBA

Advisor – Clinical Management

Contact Us

Address

4500 Great America Parkway Santa Clara, CA 9554

Phone Number

+1-408-250-2178